July 11, 2022 News by Marisa Wexler, MS Early MS Symptoms May Help Predict Diagnosis, Disease Course Some prodromal symptoms of multiple sclerosis (MS) — symptoms that are evident before the disease begins in earnest — could help to predict the course of MS, a new study proposes. In particular, its researchers suggest that MS patients with prodromal depression are more likely to be diagnosed…
May 6, 2022 News by Lindsey Shapiro, PhD MS May Influence Timely Cancer Screenings, Diagnosis: Study Breast cancer is less likely to be detected through a routine cancer screening for women with multiple sclerosis (MS), while colorectal cancer is more likely to be detected at an early stage in MS patients compared with those without the disease, a Canadian study found. “Understanding the pathways to earlier…
April 13, 2021 News by Margarida Maia, PhD Vumerity Linked to Better Quality of Life Than Tecfidera in RRMS Trial Vumerity (diroximel fumarate) is easier on the gastrointestinal tract than Tecfidera (dimethyl fumarate), and this translates into better quality of life for patients with relapsing-remitting multiple sclerosis (RRMS), a new analysis of EVOLVE-MS-2 trial data has found. The study, “Improved gastrointestinal profile with diroximel fumarate is…
September 15, 2020 Columns by Jessie Ace The Surprising Reasons You Might Be Bloated Many people with multiple sclerosis (MS) struggle with intestinal issues. There is evidence of the link between gut health and MS. Bloating is a common result of these issues. It’s super annoying and…
November 26, 2019 News by Patricia Inacio, PhD GI Symptoms with Vumerity Fewer and Milder Than Tecfidera, Phase 3 Trial Shows Vumerity (diroximel fumarate) carries fewer and less severe gastrointestinal side effects compared to Tecfidera (dimethyl fumarate), new data from a Phase 3 trial directly comparing the GI tolerability of these two relapsing-remitting multiple sclerosis (RRMS) treatments show. These results were presented at the 27th Annual Meeting of the European Charcot Foundation,…
October 11, 2019 Columns by John Connor I’m a Big Boy Now Many of us live with a reality that we’re too embarrassed to talk about, even with medical professionals. Multiple sclerosis (MS) prevents us from pooing properly — no matter how much fiber we consume or how much water we drink. I wrote about this in a recent column. As…
August 28, 2017 News by Alice Melão, MSc RRMS Patients Needed for Phase 3 Trial to Assess Adverse GI Effects of ALKS 8700 Therapy vs. Tecfidera Alkermes is funding a Phase 3 clinical trial evaluating the effects of its ALKS 8700 therapy on the gastrointestinal tracts of relapsing-remitting multiple sclerosis (RRMS) patients, compared to Tecfidera (dimethyl fumarate), according to a news release by the National Multiple Sclerosis Society. ALKS 8700, an orally administrated form of monomethyl fumarate, is still…
